We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Noninvasive Prenatal Screening Test Validated for Trisomies

By LabMedica International staff writers
Posted on 28 Oct 2015
Diagnosis of fetal aneuploidies relies on invasive testing by chorionic villous sampling (CVS) or amniocentesis in pregnancies that are identified by screening to be at high-risk for such aneuploidies.

A recently developed cell-free DNA (cfDNA) test which uses the Ion Proton sequencing platform and an algorithm that determines the relative number of chromosomal copies enabling detection of fetal trisomies has been assessed. More...


Scientists at King's College Hospital (London, UK) carried out a nested case-control study of stored maternal plasma from 242 singleton pregnancies at 11 to13 weeks’ gestation, including 201 with euploid fetuses, 35 with Down's syndrome (trisomy 21), 4 with Edwards' syndrome (trisomy 18), and 2 with Patau's syndrome (trisomy 13). A non-invasive prenatal screening test (NIPT) was used to analyze the blood samples.

The samples were analyzed with the IONA test and IONA Software (Premaitha Health plc; Manchester, UK). All 242 samples were processed with the IONA test that measures the relative amount of chromosomes 21, 18, and 13 in the maternal plasma sample to calculate a likelihood ratio to predict the presence of a trisomy. This data is coupled with the background risk associated with maternal age to determine an adjusted probability of the fetus having a trisomy of chromosome 21, 18, or 13.

Of the 242 samples; 35 were trisomy 21, 4 were trisomy 18, and 2 were trisomy 13, and therefore the IONA test detected 100% of all trisomies. This nested case-control study has demonstrated that in pregnancies considered by the combined test to be at high-risk for trisomies 21, 18, or 13, cfDNA testing of maternal plasma at 11 to 13 weeks’ gestation by the IONA test and IONA software, correctly identified all trisomic pregnancies with no false positives.

William Denman, MD, chief medical officer at Premaitha, said, “These results confirm what our customers have already reported; that the IONA test is a highly accurate, robust and simple screen for Down's syndrome and other serious genetic conditions. It is a great endorsement of the test that a scientific team has chosen to verify it. We believe this should encourage broader and appropriate uptake of NIPT, benefiting pregnant women and their families through the increased accuracy, especially the reduction in false positive results that the IONA test provides.” The study was published online on September 21, 2015, in the Journal of Ultrasound in Obstetrics and Gynaecology.

Related Links:

King's College Hospital 
Premaitha Health plc 



Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Automated Urinalysis Solution
UN-9000
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.